Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A DNA vaccine effective for eliciting an immune response against proliferating endothelial cells comprising a DNA construct operably encoding a VEGF receptor protein in a pharmaceutically acceptable carrier.

Claim 2 (original): The DNA vaccine of claim 1 wherein the VEGF receptor protein is a VEGF-2 receptor protein.

Claim 3 (original): The DNA vaccine of claim 1 wherein the VEGF receptor protein is selected from the group consisting of VEGFR-2 (KDR; SEQ ID NO: 2), VEGFR-1 (Flt-1; SEQ ID NO: 4), Flk-1 (SEQ ID NO: 6), and a functional equivalent thereof that shares at least about 80% homology therewith.

Claim 4 (original): The DNA vaccine of claim 1 wherein the DNA construct is a naked DNA construct.

Claim 5 (original): The DNA vaccine of claim 1 wherein the DNA construct is operably incorporated in a plasmid vector.

Claim 6 (original): The DNA vaccine of claim 1 wherein the DNA construct is operably incorporated in an attenuated bacterial vector.

Claim 7 (original): The DNA vaccine of claim 6 wherein the attenuated bacterial vector is selected from the group consisting of attenuated Salmonella typhimurium, Salmonella typhi, Shigella, Bacillus, Lactobacillus, BCG, Escherichia coli, Vibrio cholerae, and Campylobacter.

Claim 8 (original): The DNA vaccine of claim 6 wherein the attenuated bacterial vector is an attenuated *Salmonella typhimurium*.

Claim 9 (original): The DNA vaccine of claim 1 wherein the DNA construct is a substantially purified DNA having a polynucleotide sequence selected from the group

consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, and a functional homolog thereof that shares at least about 80% homology therewith.

Claim 10 (original): The DNA vaccine of claim 9 wherein the DNA construct is operably incorporated in an attenuated *Salmonella typhimurium* vector.

Claims 11-31 (canceled).

Claim 32 (original): An article of manufacture comprising a vaccine of claim 1 packaged in a hermetically sealed, sterile container, the container having a label affixed thereto, the label bearing printed material identifying the vaccine and providing information useful to an individual administering said vaccine to a patient.

Claim 33 (new): The DNA vaccine of claim 1 wherein the encoded VEGF receptor protein is Flk-1 (SEQ ID NO: 6).

Claim 34 (new): The DNA vaccine of claim 1 wherein the DNA construct is polynucleotide of SEQ ID NO: 5.